Signaturefd LLC Purchases 188 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

Signaturefd LLC grew its position in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 16.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,351 shares of the biotechnology company’s stock after acquiring an additional 188 shares during the period. Signaturefd LLC’s holdings in Viking Therapeutics were worth $86,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Viking Therapeutics by 44.7% during the 1st quarter. Vanguard Group Inc. now owns 7,785,724 shares of the biotechnology company’s stock worth $638,429,000 after buying an additional 2,403,820 shares during the last quarter. Avoro Capital Advisors LLC acquired a new stake in shares of Viking Therapeutics during the 1st quarter worth about $294,380,000. Perpetual Ltd lifted its stake in shares of Viking Therapeutics by 55.4% during the 3rd quarter. Perpetual Ltd now owns 1,269,152 shares of the biotechnology company’s stock worth $80,350,000 after buying an additional 452,344 shares during the last quarter. Hood River Capital Management LLC lifted its stake in shares of Viking Therapeutics by 6.3% during the 2nd quarter. Hood River Capital Management LLC now owns 714,578 shares of the biotechnology company’s stock worth $37,880,000 after buying an additional 42,650 shares during the last quarter. Finally, Westfield Capital Management Co. LP acquired a new stake in shares of Viking Therapeutics during the 1st quarter worth about $54,295,000. Institutional investors own 76.03% of the company’s stock.

Viking Therapeutics Trading Down 4.5 %

Shares of NASDAQ:VKTX opened at $74.52 on Tuesday. The stock has a market capitalization of $8.22 billion, a PE ratio of -80.13 and a beta of 1.00. The firm has a 50 day moving average of $63.83 and a 200-day moving average of $61.64. Viking Therapeutics, Inc. has a 12 month low of $9.25 and a 12 month high of $99.41.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Wednesday, October 23rd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.02. During the same quarter in the prior year, the business earned ($0.23) EPS. On average, research analysts predict that Viking Therapeutics, Inc. will post -0.98 EPS for the current fiscal year.

Insider Activity at Viking Therapeutics

In related news, CEO Brian Lian sold 112,870 shares of Viking Therapeutics stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $65.80, for a total transaction of $7,426,846.00. Following the sale, the chief executive officer now directly owns 2,354,927 shares of the company’s stock, valued at approximately $154,954,196.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Viking Therapeutics news, CEO Brian Lian sold 112,870 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $65.80, for a total transaction of $7,426,846.00. Following the sale, the chief executive officer now directly owns 2,354,927 shares of the company’s stock, valued at $154,954,196.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Greg Zante sold 131,687 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $76.61, for a total transaction of $10,088,541.07. Following the sale, the chief financial officer now directly owns 149,366 shares in the company, valued at $11,442,929.26. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 525,473 shares of company stock valued at $37,088,158. 4.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on VKTX shares. Oppenheimer restated an “outperform” rating and set a $138.00 target price on shares of Viking Therapeutics in a research note on Wednesday, September 25th. StockNews.com upgraded shares of Viking Therapeutics to a “sell” rating in a research note on Tuesday, October 15th. Raymond James lifted their price objective on shares of Viking Therapeutics from $116.00 to $118.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 25th. JPMorgan Chase & Co. initiated coverage on shares of Viking Therapeutics in a research note on Wednesday, September 11th. They issued an “overweight” rating and a $80.00 price objective for the company. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $105.00 price objective on shares of Viking Therapeutics in a research note on Thursday, September 12th. One equities research analyst has rated the stock with a sell rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Viking Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $108.60.

Viking Therapeutics Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.